Management of Dyslipidemia With Evolocumab in Kidney Transplant Recipients

Transplantation. 2024 May 1;108(5):e74-e76. doi: 10.1097/TP.0000000000004942. Epub 2024 Apr 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Anticholesteremic Agents* / therapeutic use
  • Dyslipidemias* / blood
  • Dyslipidemias* / diagnosis
  • Dyslipidemias* / drug therapy
  • Female
  • Humans
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • PCSK9 Inhibitors
  • Proprotein Convertase 9*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • evolocumab
  • Anticholesteremic Agents
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9